logo
logo
Clover Health Investments, Corp.

Clover Health Investments, Corp.

NASDAQ•CLOV
CEO: Mr. Vivek Garipalli
セクター: Healthcare
業種: Medical - Healthcare Plans
上場日: 2020-06-12
Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat. Clover Health Investments, Corp. is based in Franklin, Tennessee.
連絡先情報
3401 Mallory Lane, Suite 210, Franklin, TN, 37067, United States
201-432-2133
www.cloverhealth.com/en
時価総額
$1.04B
PER (TTM)
-17.8
0
配当利回り
--
52週高値
$4.80
52週安値
$2.01
52週レンジ
0%
順位58Top 85.6%
2.3
F-Score
改良版 Piotroski 分析
7年ファンダメンタル
弱い • 2.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2019-2025

財務ダッシュボード

Q3 2025 データ

売上高

$496.65M+50.05%
直近4四半期の推移

EPS

-$0.05+154.01%
直近4四半期の推移

フリーCF

$11.41M-76.99%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Net Premium Revenue Growth Net premiums earned reached $1.41B for nine months, increasing 38.6% driven by member growth.
Membership Base Expansion Average members grew approximately 32% over the nine months period, supporting revenue scale and data insights.
Operating Expense Leverage Adjusted SG&A as percentage of total revenues improved to 16.5% from 20.2% last year.
Cash Flow from Investing Investing activities provided $39.1M net cash, mainly from $139.5M in investment sales and maturities.

リスク要因

Medical Claims Cost Inflation Net medical claims incurred rose 51.3% to $1.15B, outpacing net premium revenue growth rate.
CMS Star Rating Decrease PPO Medicare Advantage plans rating decreased to 3.5 Stars for 2026, impacting future payment year revenue.
Stock-Based Compensation Expense Total stock-based compensation recognized was $78.7M for nine months, contributing to net loss worsening.
Continued Net Loss Net loss from continuing operations totaled $(36.2M) for nine months, worsening by 49.0% versus prior period.

見通し

Counterpart Health SaaS Growth Expanding Counterpart Health SaaS offering to external payors leverages existing AI platform for new revenue streams.
Clover Assistant Adoption Focus Focus remains on increasing adoption of Clover Assistant technology to manage medical loss ratios effectively.
Liquidity Sufficiency Confirmed Management expects current cash, investments, and projected cash flows sufficient for next twelve months obligations.
Future Accounting Standards Company currently evaluating impacts of several new FASB ASUs effective in future fiscal periods.

同業比較

売上高 (TTM)

QuidelOrtho CorporationQDEL
$2.73B
-1.9%
Teladoc Health, Inc.TDOC
$2.53B
-2.4%
Pediatrix Medical Group, Inc.MD
$1.92B
-4.2%

粗利益率 (最新四半期)

BioCryst Pharmaceuticals, Inc.BCRX
98.4%
+1.2pp
GoodRx Holdings, Inc.GDRX
93.2%
-0.9pp
NovoCure LimitedNVCR
73.2%
-3.9pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
TWST$3.01B-39.2-16.6%28.8%
LFST$2.73B-298.4-0.6%22.0%
NHC$2.63B26.010.0%8.1%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
13.8%
安定成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
50%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年2月26日
|
EPS:-$0.05
|
売上高:$467.06M
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月7日|
    売上高: $496.65M+50.1%
    |
    EPS: $-0.05+154.0%
    予想を下回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月8日|
    売上高: $477.62M+34.1%
    |
    EPS: $-0.02-308.0%
    予想を下回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月9日|
    売上高: $462.33M+33.3%
    |
    EPS: $-0.00-93.5%
    予想を上回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月3日|
    売上高: $1.37B+8.8%
    |
    EPS: $-0.09+80.5%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月8日|
    売上高: $330.99M+8.2%
    |
    EPS: $-0.02-79.2%
    予想通り

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月8日|
    売上高: $356.26M+11.3%
    |
    EPS: $0.01-116.7%
    予想を上回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月7日|
    売上高: $346.92M+7.7%
    |
    EPS: $-0.04-73.3%
    予想を上回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月14日|
    売上高: $1.26B+15.0%
    |
    EPS: $-0.45+36.6%
    予想を下回る